Comparative Pharmacology
Head-to-head clinical analysis: FOCINVEZ versus SPORANOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCINVEZ versus SPORANOX.
FOCINVEZ vs SPORANOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Inhibits fungal cytochrome P450 (CYP450)-dependent lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
200 mg orally twice daily for 3-7 days; for onychomycosis: 200 mg orally once daily for 12 weeks.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
The terminal elimination half-life of itraconazole ranges from 21 to 35 hours for single doses, increasing to approximately 34 to 42 hours at steady state. The half-life of the active metabolite, hydroxyitraconazole, is similar. This long half-life allows for once-daily or twice-daily dosing in most indications.
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Itraconazole is extensively metabolized in the liver via CYP3A4 to active metabolites, including hydroxyitraconazole. The parent drug and metabolites are primarily excreted in feces (approximately 54%) and urine (approximately 35%), with less than 1% of the dose excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal